Galenvs couples precision magnetic-nanoparticle synthesis with advanced oligonucleotide chemistry— under ISO 9001 — to accelerate diagnostic, therapeutic product development. We engage projects from lead candidate optimization through rapid synthesis, purification, QA/QC, and pilot batches in weeks instead of months, and routinely supply complex siRNA, sgRNA, ASO, Aptamers, and other heavily modified oligos at ≥95 % yield. Our proprietary nanoparticles, tunable for size, coating, and functionality, deliver
Gador S.A.
Gador is a leading Argentine pharmaceutical company. For the last 82 years, its mission has been to investigate, develop, manufacture and commercialize the best quality medicines for every patient at affordable prices. Gador continuously invests in product technology and quality control, according to international standards and maintains a large updated portfolio of pharmaceutical products. Our company is currently focused on biopharmaceutics as a source of innovation and generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a longstanding experience in the commercialization of special products, either own products or licenses from world renowned companies, such as Gilead Sciences Ltd, Astellas Pharma, Eli Lilly, Coherus, Viatris, MSD, Novartis, Cipla, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease | Gador is a leading Argentine pharmaceutical company. For the last 82 years, its mission has been to investigate, develop, manufacture and commercialize the best quality medicines for every patient at affordable prices. Gador continuously invests in product technology and quality control, according to international standards and maintains a large updated portfolio of pharmaceutical products. Our company is currently focused on biopharmaceutics as a source of innovation and generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a longstanding experience in the commercialization of special products, either own products or licenses from world renowned companies, such as Gilead Sciences Ltd, Astellas Pharma, Eli Lilly, Coherus, Sifi, Recordati, Boehringer, Viatris, MSD, Novartis, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease | Gador is a leading pharmaceutical Company that investigate, develop, manufacture and commercialize medicinal products for human use. It is based in Argentina since 1940 and today covers the whole Latin America through own affiliates or a net of exclusive distributors. Gador continuously invests in product technology, quality control and new facilities development, according to international standards and approvals such as FDA, EMA, KFDA, COFEPRIS, TGA, among others.. Our company is currently focused on innovative therapies and products, such as biopharmaceutics, oligonucleotides and gene therapies as a source of generation of new therapeutic resources for its territory, which is expanded throughout Latin America. Gador has a long-standing experience in the commercialization of special and primary care products, either own products or licenses from world renowned companies, such as Gilead Sciences, Astellas, MSD, Boehringer Ingelheim, Recordati, Viatris, Sifi, Galderma, Besins, among others. As a leader company in the market, Gador has undertaken an ambitious program in this area, which involves: Licenses of new products approved or at their last clinical development stage Commercialization of a new-generation biosimilar Development and commercialization of new biopharmaceuticals with focus in special products and rare disease In addition, Gador´s main shareholders have created a new development company: Qualix Dot (Design on Therapies). Qualix DoT is the research and development pharmaceutical company of Qualix Ventures.The purpose of Qualix DoT is to explore, drive, and collaborate in world-class innovative projects that come from academic or industrial initiatives by mainly repurposing known compounds for new indications. Qualix DoT adopts a collaborative business model whereby it works in partnership with academic, industrial and patients’ organizations. Biopharmaceuticals – rare disease – oncology – biosimilars – CAR T – Oligonucleotides y Repurposing
FYR
FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, better trials, better drugs and better outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCsTM, to enrich extracellular vesicles from diseased cells and reveal a treasure trove of proteins and nucleic acids. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential treatment options. The unparalleled view provided by FYR’s multiomics approach can transform personalized patient care, from screening through therapy selection and monitoring.
Fullscript
Patients are taking control of their own health. They want care that’s personalized, proactive, and continuous. They’re forgoing clinical expertise for convenience, but they don’t have to. Fullscript helps large healthcare systems meet this moment with an expanding platform of services that turn today’s gaps into tomorrow’s growth. Capitalize on the shift in patient demands without overwhelming your clinical staff and workflows.
Fulgent Genetics
Fulgent is a technology-driven Biopharma services company boasting a robust portfolio of clinical diagnostic, research solutions and R&D capabilities. Our clinical diagnostic and BioPharma business units provide a wide array of services including molecular diagnostic testing, comprehensive NGS genetic testing, RNASeq, targeted DNA / RNA panels (FFPE, Liquid Biopsy, Heme), single cell and spatial analysis (10x Genomics), proteomics (Olink) and top-tier anatomic pathology laboratory services (Immunohistochemistry (IHC), RNAscope (ISH), Akoya, Flow Cytometry). These offerings are meticulously crafted to support biomarker development in immuno-Oncology research complemented with actionable diagnostic insights, ultimately enhancing the quality of patient care. With a dedicated focus on patient screening and enrollment testing, biomarker analysis, and companion diagnostics for clinical research, Pharma Clinical trials, and contract research, Fulgent’s BioPharma Services cater to the specific needs of the pharmaceutical industry. With facilities situated in the US, China, and Australia, our overarching mission is to revolutionize the genomic diagnostic landscape, positioning ourselves as a fully integrated precision medicine company poised to drive advancements in healthcare. Fulgent’s latest step forward to this commitment is approval for the largest CE-marked Clinical Exome gene panel for genetic testing, underscoring our dedication to meeting the highest standards of regulatory compliance & quality. | Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.
FUJIFILM Healthcare Americas Corporation
Advanced Orthopedic Imaging Solutions. Discover Fujifilm’s cutting-edge orthopedic imaging portfolio, featuring state-of-the-art digital radiography detectors, rooms, portables, fluoroscopic c-arms, MRI and CT systems, all designed to streamline workflow and enhance your patient care. Our portfolio of solutions can help reduce your procedure times while delivering exceptional imaging with comfort, speed and ease. | Fujifilm is a market leader and progressive partner with pulmonary practices across the US, improving patient outcomes through innovative imaging technologies. Learn about the latest advances in high-quality pulmonology imaging, including Fujifilm’s: • 500 Series Bronchoscopes, designed for effective observation, diagnosis, and treatment of the trachea and bronchial tree • EBUS bronchoscope with a 10-degree forward oblique view • Small, lightweight Ultrasonic Mini Probe System • ELUXEO Imaging System | As a longstanding and trusted partner, FUJIFILM Healthcare Americas Corporation understands today’s biggest enterprise imaging challenges. With an advanced cybersecurity architecture, its cloud and AI-enabled Synapse® Enterprise Imaging portfolio is a single-vendor system that delivers a seamless experience tailored to each specialty and workflow, while providing a holistic patient view, alleviating resource constraints, and reducing IT overhead. | FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis, and treatment of diseases. Fujifilm’s innovative portfolio includes solutions spanning diagnostic imaging, enterprise imaging, endoscopic imaging, surgical imaging, and in-vitro diagnostics. The company is headquartered in Lexington, Massachusetts. For more information, please visit healthcaresolutions-us.fujifilm.com.
Fraunhofer MEVIS
The Fraunhofer Institute for Digital Medicine MEVIS, based in Bremen, Germany, is a leading research institution dedicated to improving patient outcomes and shaping a sustainable healthcare system through innovative software solutions for personalized and precise medical care. Part of the Fraunhofer-Gesellschaft, Europe’s premier organization for applied research, Fraunhofer MEVIS bridges the gap between research and clinical practice by translating science into real-world solutions. The institute collaborates with partners to detect diseases earlier, enable precise therapy decisions, tailor treatments, and measure treatment success. Utilizing AI, deep learning, image and data analysis, biophysical modeling, and intelligent visualization, Fraunhofer MEVIS creates systems for computer-assisted decision-making and intervention, transforming patient care and advancing the future of medicine.
Fovia AI
Explore Artificial Intelligence solutions from Fovia AI, Inc. along with Advanced Visualization technology from parent company Fovia, Inc.
Foundation Medicine, Inc.
Foundation Medicine, Inc. transforms cancer care by developing comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.